These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32311018)

  • 1. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
    Yao J; Jiang X; You JHS
    Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Marquez-Megias S; Nalda-Molina R; Sanz-Valero J; Más-Serrano P; Diaz-Gonzalez M; Candela-Boix MR; Ramon-Lopez A
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
    Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
    Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
    Patel RN; Nigam GB; Jatale RG; Desai D; Makharia G; Ahuja V; Limdi JK
    Indian J Gastroenterol; 2020 Apr; 39(2):176-185. PubMed ID: 32483692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis.
    Manceñido Marcos N; Novella Arribas B; Mora Navarro G; Rodríguez Salvanés F; Loeches Belinchón P; Gisbert JP
    Dig Liver Dis; 2024 Mar; 56(3):421-428. PubMed ID: 37422409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    Dutt K; Vasudevan A
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
    [No Abstract]   [Full Text] [Related]  

  • 10. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
    Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
    Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
    J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    Martelli L; Olivera P; Roblin X; Attar A; Peyrin-Biroulet L
    J Gastroenterol; 2017 Jan; 52(1):19-25. PubMed ID: 27665099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
    Samuels A; Whaley KG; Minar P
    Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.